FlowSense was acquired by Baxter in September 2013.
FlowSense’s product, based on patented optical sensing technology, allows continuous, real-time data to be collected automatically and made accessible to clinicians at any time.
Measurement of urine output is a key indicator of a patient’s fluid balance and renal condition, particularly in the critical care setting. Acute kidney injury occurs in approximately 5% of all hospitalized patients and in 30% of critical care patients, resulting in higher costs of care and higher mortality rates.
Mechanical urine meters, which are labor intensive and based on manual volume readings, do not provide urine output data necessary for timely detection and treatment of kidney injury.